PL3529274T3 - Przeciwciało monoklonalne i sposób jego stosowania w leczeniu tocznia - Google Patents

Przeciwciało monoklonalne i sposób jego stosowania w leczeniu tocznia

Info

Publication number
PL3529274T3
PL3529274T3 PL17862072.0T PL17862072T PL3529274T3 PL 3529274 T3 PL3529274 T3 PL 3529274T3 PL 17862072 T PL17862072 T PL 17862072T PL 3529274 T3 PL3529274 T3 PL 3529274T3
Authority
PL
Poland
Prior art keywords
lupus
treatment
monoclonal antibody
monoclonal
antibody
Prior art date
Application number
PL17862072.0T
Other languages
English (en)
Inventor
Pradip Nair
Ravindra Belavinakodige Sadashivarao
Ramakrishnan Melarkode
Original Assignee
Biocon Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocon Limited filed Critical Biocon Limited
Publication of PL3529274T3 publication Critical patent/PL3529274T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL17862072.0T 2016-10-21 2017-10-17 Przeciwciało monoklonalne i sposób jego stosowania w leczeniu tocznia PL3529274T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201641036145 2016-10-21
PCT/IB2017/056428 WO2018073734A1 (en) 2016-10-21 2017-10-17 A monoclonal antibody and a method of use for the treatment of lupus

Publications (1)

Publication Number Publication Date
PL3529274T3 true PL3529274T3 (pl) 2024-09-09

Family

ID=62019383

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17862072.0T PL3529274T3 (pl) 2016-10-21 2017-10-17 Przeciwciało monoklonalne i sposób jego stosowania w leczeniu tocznia

Country Status (12)

Country Link
US (2) US11242401B2 (pl)
EP (1) EP3529274B1 (pl)
JP (1) JP7071974B2 (pl)
KR (1) KR102514528B1 (pl)
AU (2) AU2017344462B2 (pl)
CA (1) CA3039855A1 (pl)
DK (1) DK3529274T3 (pl)
ES (1) ES2991182T3 (pl)
IL (1) IL266106A (pl)
PL (1) PL3529274T3 (pl)
PT (1) PT3529274T (pl)
WO (1) WO2018073734A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201001467A1 (ru) 2008-03-14 2011-06-30 Биокон Лимитед Моноклональное антитело и способ его использования
CA2920368C (en) 2013-07-23 2023-03-21 Centro De Inmunologia Molecular Use of a cd6 binding partner and method based thereon
JP7065085B2 (ja) * 2016-10-18 2022-05-11 バイオコン・リミテッド Ｃｄ６のリン酸化を低減させるためのイトリズマブの使用
PL3529274T3 (pl) 2016-10-21 2024-09-09 Biocon Limited Przeciwciało monoklonalne i sposób jego stosowania w leczeniu tocznia
MX2021010283A (es) * 2019-02-26 2021-09-30 Equillium Inc Composiciones de anticuerpo anti-cd6 y metodos para tratar lupus.
WO2021138454A1 (en) * 2019-12-30 2021-07-08 City Of Hope Methods of making and using regulatory t cells and effector t cells having chimeric antigen receptors targeted to cd6, cd19, and/or an il-13r for treatment of autoimmune disorders and cancers

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US699755A (en) 1902-03-06 1902-05-13 Ira G Hoag Train-order box in connection with semaphores.
US6162432A (en) 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
EP0631783A1 (en) 1993-06-03 1995-01-04 Mitsubishi Chemical Corporation Antiviral combinations of 2',3'-di-deoxyribonucleosides with 6-benzyl-1-ethoxymethyl-5-substituted uracil derivatives
CA2175247A1 (en) 1993-11-02 1995-05-11 Barton F. Haynes Cd6 ligand
US5998172A (en) 1993-11-02 1999-12-07 Duke University Anti-CD6 ligand antibodies
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
CU22584A1 (es) 1995-11-17 1999-11-03 Centro Inmunologia Molecular Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis
SI9720021A (sl) 1996-03-20 1999-04-30 Hoechst Marion Roussel Triciklične spojine s specifično aktivnostjo za integrine, zlasti za integrine alfavbeta3, postopki za njihovo pripravo in intermediati teh postopkov, njihova aplikacija kot zdravila in farmacevtski sestavki, ki jih vsebujejo
CA2282410A1 (en) 1997-03-03 1998-10-01 Bristol-Myers Squibb Company Monoclonal antibodies to human cd6
WO1998047531A2 (en) 1997-04-21 1998-10-29 Arch Development Corporation Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy
WO2000058362A1 (en) 1999-03-26 2000-10-05 Human Genome Sciences, Inc. Neutrokine-alpha binding proteins and methods based thereon
MXPA01011279A (es) 1999-05-07 2002-07-02 Genentech Inc Tratamiento de enfermedades autoinmunes con antagonistas que se unene a los marcadores de superficie, de celulas b.
EP1263960A2 (en) 2000-03-16 2002-12-11 Genentech, Inc. Anti-tissue factor antibodies with enhanced anticoagulant potency
JP2003534022A (ja) 2000-05-26 2003-11-18 スミスクライン・ビーチャム・コーポレイション Ｒａｎｋリガンド介在障害の治療に有用な抗−ｒａｎｋリガンドモノクローナル抗体
ES2192128B1 (es) 2001-04-27 2005-01-01 Universidad De Vigo Anticuerpo monoclonal humano que reconoce especificamente la molecula humana cd69, y su uso en terapia.
CA2454587C (en) 2001-07-25 2012-11-13 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
WO2004019861A2 (en) 2002-08-28 2004-03-11 Pharmacia Corporation Stable ph optimized formulation of a modified antibody
JP2006521387A (ja) 2003-03-04 2006-09-21 アレクシオン ファーマシューティカルズ， インコーポレイテッド 寛容誘導抗原提示細胞による抗原提示の誘導によって自己免疫疾患を治療する方法
CN1798575A (zh) 2003-04-04 2006-07-05 健泰科生物技术公司 高浓度抗体和蛋白制剂
AU2005214382B2 (en) 2004-02-19 2011-08-04 Genentech, Inc. CDR-repaired antibodies
JP5139800B2 (ja) 2004-06-03 2013-02-06 ノビミューン エスアー 抗ｃｄ３抗体およびその使用方法
DK1817340T3 (da) 2004-11-12 2012-08-13 Xencor Inc Fc-varianter med ændret binding til fcrn
BRPI0606867A2 (pt) 2005-01-28 2009-07-21 Wyeth Corp formulação lìquida; forma de dosagem unitária farmacêutica; kit; recipiente; método para aumentar a estabilidade de um polipeptìdeo de ligação a antìgeno numa formulação; método para preparar uma forma de dosagem unitária farmacêutica; formulação estável; formulação; e produto terapêutico
EA015860B1 (ru) 2005-10-13 2011-12-30 Хьюман Дженом Сайенсиз, Инк. Способы лечения аутоиммунных заболеваний при использовании антагониста нейтрокина-альфа
BRPI0713421A2 (pt) 2006-06-14 2012-03-13 Imclone Systems Incorporated Formulação liofolizada, formulação aquosa adequada para a liofilização, e, métodos para estabilizar am anticorpo e para tratar um mamífero
DE102006029838A1 (de) 2006-06-27 2008-01-03 Henkel Kgaa Wasch- oder Behandlungsmittelportion mit Löslichkeits- und/oder Dispergierfähigkeitsgradient
JP2010512356A (ja) 2006-12-11 2010-04-22 エフ．ホフマン−ラ ロシュ アーゲー 非経口ａベータ抗体製剤
CN101199483B (zh) 2006-12-14 2011-01-26 上海中信国健药业股份有限公司 一种稳定的抗her2人源化抗体制剂
KR101482959B1 (ko) 2006-12-26 2015-01-15 센트로 데 인뮤놀러지아 모레큘러 Ｂ-세포 만성 림프구성 백혈병의 진단 및 치료에 유용한 종양 세포에서 세포사멸을 유도할 수 있는 약학 조성물
PT2119452T (pt) 2006-12-26 2020-05-08 Ct Inmunologia Molecular Composição farmacêutica que compreende um anticorpo monoclonal anti-cd6 utilizado no diagnóstico e tratamento de artrite reumatoide
CA2674608A1 (en) 2007-01-09 2008-07-17 Wyeth Anti-il-13 antibody formulations and uses thereof
AU2008219684B2 (en) 2007-02-28 2014-04-17 Merck Sharp & Dohme Corp. Engineered anti-IL-23R antibodies
US20090208492A1 (en) 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
EP2170268A2 (en) 2007-06-25 2010-04-07 Amgen, Inc. Compositions of specific binding agents to hepatocyte growth factor
WO2009037190A2 (en) 2007-09-21 2009-03-26 F. Hoffmann-La Roche Ag Pharmaceutical formulation for il-ir antibody
EA201001467A1 (ru) 2008-03-14 2011-06-30 Биокон Лимитед Моноклональное антитело и способ его использования
AU2010320515B2 (en) 2009-11-20 2013-05-02 Biocon Limited Formulations of antibody
US9910039B2 (en) * 2011-07-01 2018-03-06 Beckman Coulter, Inc. Regulatory T cells and methods of identifying, obtaining and using to treat immuno-based disorders
CN102559636B (zh) 2011-12-30 2014-03-12 百泰生物药业有限公司 用于白血病和自身免疫疾病的抗体融合蛋白及其制备方法
KR102062784B1 (ko) * 2013-07-23 2020-01-07 바이오콘 리미티드 단백질 내 푸코실화 수준을 제어하는 방법
CA2920368C (en) 2013-07-23 2023-03-21 Centro De Inmunologia Molecular Use of a cd6 binding partner and method based thereon
WO2017218750A1 (en) 2016-06-15 2017-12-21 The Cleveland Clinic Foundation Novel anti-cd6 antibodies for treating t-cell mediated conditions
JP7065085B2 (ja) 2016-10-18 2022-05-11 バイオコン・リミテッド Ｃｄ６のリン酸化を低減させるためのイトリズマブの使用
PL3529274T3 (pl) 2016-10-21 2024-09-09 Biocon Limited Przeciwciało monoklonalne i sposób jego stosowania w leczeniu tocznia
SG11202008149RA (en) 2018-02-27 2020-09-29 Equillium Inc Anti cd6 antibodies for treating severe asthma

Also Published As

Publication number Publication date
AU2017344462B2 (en) 2024-07-25
JP2020503251A (ja) 2020-01-30
IL266106A (en) 2019-06-30
US11242401B2 (en) 2022-02-08
ES2991182T3 (es) 2024-12-02
EP3529274B1 (en) 2024-04-17
US20190241670A1 (en) 2019-08-08
NZ752720A (en) 2025-05-02
PT3529274T (pt) 2024-06-21
CA3039855A1 (en) 2018-04-26
EP3529274A1 (en) 2019-08-28
WO2018073734A1 (en) 2018-04-26
KR20190066067A (ko) 2019-06-12
EP3529274A4 (en) 2020-08-19
AU2024227640A1 (en) 2024-11-14
US20220227880A1 (en) 2022-07-21
KR102514528B1 (ko) 2023-03-27
AU2017344462A1 (en) 2019-05-02
DK3529274T3 (da) 2024-06-17
JP7071974B2 (ja) 2022-05-19

Similar Documents

Publication Publication Date Title
ZA202105676B (en) Anti-trem2 antibodies and related methods
IL272218A (en) ANTI-SIRP-ALPHA ANTIBODIES AND RELATED METHODS
IL308156B1 (en) Anti-C1S antibodies and methods of using them
IL265800A (en) Anti-lag-3 antibodies and methods of using them
SG10201912879YA (en) Anti-sirp-alpha antibodies and methods of use thereof
PL3426686T3 (pl) Humanizowane przeciwciała anty-pacap i ich zastosowanie
SG10201912563XA (en) Anti-tim-3 antibodies and methods of use thereof
ZA201608305B (en) Monoclonal antibodies against her2 epitope and methods of use thereof
IL263611B (en) Antibodies specific to pd-l1 and methods of using them
IL252929B (en) Anti-acth antibodies from humans and their use
ZA202003858B (en) Monoclonal antibodies and methods for using same
SG11201707886WA (en) Humanized anti-c1s antibodies and methods of use thereof
IL266106A (en) Monoclonal antibody and method of use for treatment of lupus
PL3313877T3 (pl) Humanizowane przeciwciała przeciwko białku tau(pS422) i sposoby stosowania
IL273538A (en) Anti-TRKB Monoclonal Antibodies and Methods of Use
SMT202200360T1 (it) Anticorpi umanizzati anti clever-1 e loro utilizzo
ZA201807132B (en) Humanized anti-basigin antibodies and the use thereof
ZA201805051B (en) Egfl6 specific monoclonal antibodies and methods of their use
GB201616596D0 (en) Epitope and antibodies